JULY 2026

LOUISIANA BOARD OF PHARMACY

Newsletter to Promote Pharmacy and Drug Law Compliance.

New Rules (26-07-835)

The Louisiana Board of Pharmacy completed the rulemaking process for four regulatory projects with publication of the final rules in the May 20, 2026 edition of the *Louisiana Register*, with immediate effective dates. The Board distributed three separate email notices regarding the progress of these regulatory projects, in addition to maintaining the information on the Regulatory Projects page of the Board's website.

Regulatory Project 2026-01 – Controlled Dangerous Substances (CDS) amended Chapter 27, relative to CDS, to streamline the regulatory framework by adopting federal regulations by reference, consolidating any provisions that differ from the Code of Federal Regulations (CFR) into Section 2713, and repealing all remaining sections containing redundant requirements.

Regulatory Project 2026-02 – Remote Access by a Pharmacy Technician amended Section 1145 of the Board's rules relative to remote access to prescription drug orders, medical orders, and chart orders. The rule change adds pharmacy technicians to those authorized under the rule and includes required safeguards for records, supervision requirements for pharmacy technicians, and policies to address quality assurance standards.

Regulatory Project 2026-03 – Community Pharmacy repealed Chapter 13 of the Board's rules relative to community pharmacy. During the Board's review of its rules in compliance with the governor's Executive Order No. JML 25-038 and Act 102 of the 2024 Regular Session, the regulations in Chapter 13 were determined to be unnecessary because its requirements are already addressed in Chapter 11, Pharmacies.

Access the National Pharmacy Compliance News

A Service of the National Association of Boards of Pharmacy Foundation® (NABPF®)

New Rules (26-07-835) *(cont)*

Regulatory Project 2026-04 – Institutional Pharmacy amended Section 1705 and repealed Sections 1715, 1717, 1719, 1721, 1723, and 1725 of the Board's rules relative to institutional pharmacy. The change in Section 1705 removes the restriction on the type of pharmacy permit that may be issued to a pharmacy located within an institutional facility and removes Section 1705.B and Section 1705.C regarding hospital and correctional center pharmacies, which are addressed in Chapter 15 and Chapter 18 of the Board's rules. The repeal of Sections 1715, 1717, 1719, 1721, 1723, and 1725 removes regulations regarding drug abuse treatment center pharmacies that were determined to be unnecessary, following the Board's review of its rules in compliance with the governor's Executive Order No. JML 25-038 and Act 102 of the 2024 Regular Session. Drug abuse treatment center pharmacies will adhere to the remainder of Chapter 17 and Chapter 11 of the Board's rules.

Rulemaking Activity (26-07-836)

The Board initiated the rulemaking process for four regulatory projects with publication of the notices of intent in the May 2026 edition of the *Louisiana Register,* publication on the Board's website, and a notification distributed via email. The projects include the following:

- Regulatory Project 2025-454 – Pharmacists (formerly: Solicitation of Comments)
- Regulatory Project 2026-05 – Off-Site Services
- Regulatory Project 2026-06 – Advertising
- Regulatory Project 2026-07 – Pharmacy Interns Professional Experience

The Board's regulatory activity, which includes detailed information regarding each proposal and project, can be monitored in the Board's Rulemaking Activity section of its website.

Pharmacist Responsibility (26-07-837)

If you are the pharmacist-in-charge (PIC) of a pharmacy, it is your responsibility to ensure that all personnel you allow to perform professional functions in your pharmacy have the proper credentials that are active and current. If you are a staff pharmacist or a relief pharmacist, it is your responsibility to ensure that all personnel you allow to assist you in the pharmacy are properly credentialed with an active and current credential. Remember, you may verify the status of any credential on the Board's website.

Spotlight on Compliance (26-07-838)

Licensees should be aware of recent changes to Chapter 27 of the Board's regulations, often referred to as the "Controlled Substance Chapter."

On May 20, 2026, the promulgation of Regulatory Project 2026-01 was completed, with the final rule being published in the *Louisiana Register* (Volume 52, May edition, page 686). This project streamlines Chapter 27 by adopting federal regulations by reference, consolidating any provisions that differ from the CFR into Section 2713, and repealing all remaining sections containing redundant requirements. The project also changes distributor reporting requirements.

Prior to this project, Chapter 27 largely mirrored federal regulations (21 CFR Parts 1300-1399). In addition to reducing the size of the chapter, adopting

Spotlight on Compliance (26-07-838) *(cont)*

these by reference will prevent confusion during the time between when a federal regulation changes and when the state change could be promulgated in response.

Now, Section 2713 – General Requirements contains state regulations that differ from federal regulations. For example, the Board requires pharmacies to conduct an annual complete CDS inventory, where the federal requirement is a biennial inventory.

If you are using a previously downloaded edition of the Board's laws and rules, recent rule changes may not be included. Current Board regulations, the CFR, and Louisiana Revised Statutes are all available on the Board's website, under the Resources tab, then selecting "Laws & Regulations."

To follow regulatory projects for new or amended rules, select "Rulemaking Activity" under the Public Library tab.

Changes Pharmacists May Make to Schedule II Paper Prescriptions (26-07-839)

On October 18, 2022, Drug Enforcement Administration (DEA) issued guidance titled *Changes Pharmacists May Make to Schedule II Paper Prescriptions*. The guidance document remains in effect until DEA codifies new regulations, or until the guidance is modified or withdrawn. The guidance expresses that pharmacists should adhere to state regulations **or policy** regarding changes that a pharmacist may make to a Schedule II prescription after oral consultation with the prescriber.

On May 6, 2026, anticipating the completion of Regulatory Project 2026-01, which repealed several regulations including the one addressing changes pharmacists may make to a Schedule II prescription, the Board adopted that regulation as policy. The policy will remain in effect until DEA codifies new regulations, modifies or withdraws its guidance, or the Board rescinds the policy.

The policy, which uses the same language as the repealed regulation, states:

> Completion of Prescription Form. In the event a pharmacist receives a prescription for a controlled substance listed in Schedule II lacking certain required information, the pharmacist may consult with the prescriber (but not the prescriber's agent) to clarify the prescriber's intent. Following a consultation with the prescriber and the appropriate documentation thereof on the prescription form:
>
> a. a pharmacist may record changes to the following data elements on the prescription form:
>
> i. patient's address;
>
> ii. drug strength;
>
> iii. quantity prescribed; or
>
> iv. directions for use;
>
> b. a pharmacist may add the following data elements on the prescription form:
>
> i. patient's address;
>
> ii. drug dosage form; or
>
> iii. prescriber's DEA registration number; however,
>
> c. a pharmacist shall never make changes to or add the following data elements on the prescription form:
>
> i. patient's name;
>
> ii. date of issue;
>
> iii. drug name (except for generic interchange as permitted by law); or
>
> iv. prescriber signature.

Pulse by NABP On Track to Be Available to Dispensers Before DSCSA Deadline (26-07-840)

At the 122nd NABP Annual Meeting in May 2026, the National Association of Boards of Pharmacy® (NABP®) debuted new enhancements to the Pulse by NABP™ Product Verification Service (PVS). Through the PVS, regulators can proactively verify product serial numbers with the manufacturer or record and potentially identify illegitimate products. Currently, more than 150 regulators are using the platform to help identify illegitimate products in the pharmacy supply chain.

As the November Drug Supply Chain Security Act (DSCSA) compliance deadline approaches, NABP is in the process of onboarding chain pharmacies and will soon be inviting independent pharmacies to create an account and claim their facility's profiles.

Pulse enables dispensers to easily communicate with trading partners and respond to regulators in a user-friendly system. Creating an account and claiming a facility profile is free to dispensers, along with many other important features, such as searching for trading partner information, validating trading partner identity, and accessing contact information.

Visit *pulse.pharmacy* to learn more about Pulse by NABP.

Disciplinary and Other Licensure Actions (26-07-841)

During its May 6, 2026 meeting, the Board acted on the following matters:

Demetria Ann Washington (PTC.032621): For her failure to follow a directive from the Board, the Board suspended her credential for an indefinite period of time; and further, assessed a fine of $500 plus hearing, administrative, and investigative costs; and further, conditioned the acceptance of any future application upon the satisfaction of certain requirements identified within the hearing order.

Kristin Marie Picou (PST.022095): For diversion of controlled substances (CS), which was self-reported, the Board suspended her license for six months beginning on May 6, 2026, and terminating on November 6, 2026, suspended the suspension, then placed the license on probation for the period of suspension, subject to a condition of probation; and further, assessed administrative and investigative costs.

My Pharmacy of Monroe, LLC, dba My Pharmacy of Monroe (Monroe, LA) (PHY.008141-IR): For its failure to designate a new PIC within 10 days of the departure of the prior PIC, the Board assessed a fine of $2,500 plus administrative and investigative costs.

LaToya Dominique Batiste (PST.020797): For failing to report an adverse action as part of the pharmacist license renewal application for the year 2026, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of $1,000 plus administrative costs.

Chrysalis Group, LLC, dba Manor Pharmacy II (Katy, TX) (PHY.009007-NR): For dispensing 15 prescriptions into Louisiana from January 1 to April 14, 2026, with an expired Louisiana nonresident pharmacy permit, the Board assessed a fine of $5,000 plus administrative costs.

Darcell Nicole Duhon (CPT.017860): For diversion of CS, the Board revoked her credential; and further, prohibited her from applying or reapplying to practice or assist in the practice of pharmacy.

Calendar Notes (26-07-842)

The next quarterly meetings of the Board and some of its committees for 2026 are tentatively scheduled for August 11-12 and November 17-18, 2026. Upcoming events can be found on the home page of the Board's website.

Special Note (26-07-843)

The *Louisiana Board of Pharmacy Newsletter* is considered an official method of notification to pharmacies, pharmacists, pharmacy interns, pharmacy technicians, and pharmacy technician candidates credentialed by the Board. **These *Newsletters* will be used in administrative hearings as proof of notification.** Please read them carefully. Electronic copies dating back to 1998 are posted on the Board's website.

The Louisiana Board of Pharmacy News is published by the Louisiana Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

M. Joseph Fontenot, Jr, RPh - State News Editor
Lemrey "Al" Carter, PharmD, MS, RPh - National News Editor & Executive Editor
Megan Pellegrini - Publications and Editorial Manager

3388 Brentwood Drive | Baton Rouge, LA 70809-1700 | www.pharmacy.la.gov